Results 231 to 240 of about 4,960,896 (346)
Editorial: Bridging translational gaps in cardiovascular disease through large animal research. [PDF]
Amorós-Figueras G +3 more
europepmc +1 more source
Glymphatic Dysfunction Reflects Post‐Concussion Symptoms: Changes Within 1 Month and After 3 Months
ABSTRACT Objective Mild traumatic brain injury (mTBI) may alter glymphatic function; however, its progression and variability remain obscure. This study examined glymphatic function following mTBI within 1 month and after 3 months post‐injury to determine whether variations in glymphatic function are associated with post‐traumatic symptom severity ...
Eunkyung Kim +3 more
wiley +1 more source
Rare case of young cardiac amyloidosis: difficult diagnostic pathway in routine clinical care. [PDF]
Chumakova OS +7 more
europepmc +1 more source
Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease
ABSTRACT Objective Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.
Tuhin Virmani +8 more
wiley +1 more source
Case Report: Low-profile covered stents in CHD: the role of Gore Viabahn (VBX) stents. [PDF]
Rebonato M +4 more
europepmc +1 more source
Knowledge Sharing Contribution to Project Risk Management: a Study in the Software Industry
Yóris Linhares Souza +3 more
openalex +2 more sources
ABSTRACT Objective Accurate localization of epileptogenic tubers (ETs) in patients with tuberous sclerosis complex (TSC) is essential but challenging, as these tubers lack distinct pathological or genetic markers to differentiate them from other cortical tubers.
Tinghong Liu +11 more
wiley +1 more source
Lancet2: Improved and accelerated somatic variant calling with joint multi-sample local assembly graphs. [PDF]
Musunuri RL +13 more
europepmc +1 more source
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source

